Willenbacher, Wolfgang

Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats

Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., Eller, K., Wolf, D., Seifert, M., Sun, C. C., et al. (2011) · Blood

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 189

Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats

Theurl, M., Nairz, M., Schroll, A., Sonnweber, T., Asshoff, M., Haschka, D., Seifert, M., Willenbacher, W., Wilflingseder, D., Posch, W., et al. (2014) · Haematologica

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 42

The cancer patient’s perspective of COVID-19-induced distress—A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Koinig, K. A., Arnold, C., Lehmann, J., Giesinger, J., Köck, S., Willenbacher, W., Weger, R., Holzner, B., Ganswindt, U., Wolf, D., et al. (2021) · Cancer Medicine

Cancer survivorship and careCOVID-19 and Mental Health

Cited by 34

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

Raje, N., Roodman, G. D., Willenbacher, W., Shimizu, K., García-Sanz, R., Terpos, E., Kennedy, L., Sabatelli, L., Intorcia, M., & Hechmati, G. (2018) · Journal of Medical Economics

Bone health and treatmentsHealth Systems, Economic Evaluations, Quality of Life

Cited by 25

An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma

Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., Garcia-Sanz, R., Durie, B., Legiec, W., Krejci, M., Laribi, K., Zhu, L., et al. (2017) · Clinical Lymphoma Myeloma and Leukemia

Bone health and treatmentsMultiple Myeloma Research and Treatments

Cited by 14